NDA 021610 · Endo Operations
Opana Er
Oxymorphone Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jun 22, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
15 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 22, 2006 Original approval · Type 3 - New Dosage Form Other
7 products under this application
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OPANA ER · OXYMORPHONE HYDROCHLORIDE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxymorphone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute PainPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00226395 · 320 participants · Start Sep 2004
Drug: Oxymorphone immediate release · For: Acute Pain
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 21 sites in all
- Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic EfficacyPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00904280 · 239 participants · Start Mar 2001 · Primary completion Jul 2003
Drug: Oxymorphone ER · For: Cancers, Pain; Lower Back Pain
Sites: Tucson, Arizona
- Oxymorphone Extended Release in Patients With Cancer or Neuropathic PainPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00911261 · 223 participants · Start Aug 2003 · Primary completion Mar 2005
Drug: Oxymorphone Extended Release · For: Chronic Pain; Neuropathic Pain; Cancer
- Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00225797 · 160 participants · Start Nov 2004
Drug: Oxymorphone Extended Release · For: Chronic Pain
Sites: Hueytown, Alabama; Phoenix, Arizona; Colorado Springs, Colorado · 33 sites in all
- Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic PainPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00911287 · 129 participants · Start Jun 2003 · Primary completion Jan 2004
Drug: Oxymorphone extended release · For: Pain; Chronic Disease
- Post-operative Efficacy and Safety StudyPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00904085 · 122 participants · Start Apr 2003 · Primary completion Jun 2003
Drug: Oxymorphone IR · For: Post-operative Pain
- Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant PainPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00226421 · 120 participants · Start Oct 2004
Drug: Oxymorphone Extended Release · For: Chronic Pain
Sites: Hueytown, Alabama; Phoenix, Arizona; Colorado Springs, Colorado · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.
da Costa BR, Pereira TV, Saadat P, et al. · BMJ 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Equianalgesic potency ratios of opioids used in patient-controlled analgesia: A network meta-analysis.
Dinges HC, Schubert AK, Rücker G, et al. · J Opioid Manag 2022 · Systematic Review, Network Meta-Analysis
- A systematic review of oxymorphone in the management of chronic pain.
Mayyas F, Fayers P, Kaasa S, et al. · J Pain Symptom Manage 2010 · Meta-Analysis, Systematic Review
- Association of Physical Activity With Bioactive Lipids and Cardiovascular Events.
Hoshi RA, Liu Y, Luttmann-Gibson H, et al. · Circ Res 2022 · Clinical Trial, Research Support, N.I.H., Extramural
- Opioids for agitation in dementia.
Brown R, Howard R, Candy B, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids?
Zimmermann M, Richarz U · Pain Pract 2014 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Endo Operations
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.